All articles by Vidya Sagar Maddela
Vidya Sagar Maddela
Scinai to acquire Pincell for its rare skin disease drug PC111
The acquisition includes Pincell’s lead candidate, PC111, a fully human monoclonal antibody targeting rare and severe skin diseases, without suppressing the immune system
Genmab’s Tivdak approved in Japan to treat cervical cancer
Tivdak is an antibody-drug conjugate (ADC) co-developed and co-commercialised by Genmab and Pfizer, combining Genmab’s human monoclonal antibody targeting tissue factor with Pfizer’s ADC technology
Merck’s pneumococcal vaccine Capvaxive approved in EU
Capvaxive is designed for active immunisation, as a single dose, against invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals aged 18 and older
Exelixis obtains expanded FDA approval for Cabometyx to treat NET
The FDA approval expands the Cabometyx indication to include unresectable, locally advanced, or metastatic pancreatic and extra-pancreatic NET in patients aged 12 and above
Merck, Hengrui Pharma sign licensing agreement for HRS-5346
Merck obtains the rights to develop, manufacture, and commercialise HRS-5346 worldwide, excluding the Greater China region, in exchange for an upfront payment of $200m and milestone payments up to $1.77bn
Character Bio secures $93m funding to advance precision medicine for AMD
Character Bio intends to use the funding to support Phase 1 and Phase 2 studies for its lead candidates CTX203 and CTX114, along with the expansion of its precision therapies pipeline
Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica
First Logica-identified candidate marks a progression-based milestone in ongoing partnership with Pioneering Medicines, Flagship Pioneering’s in-house drug development unit
Novo Nordisk signs licensing deal for obesity and diabetes drug
Novo Nordisk will obtain global rights to develop and market UBT251, excluding China mainland, Hong Kong, Macau, and Taiwan, in exchange for a $200m upfront payment and up to $1.8bn in milestone payments
EMA accepts GSK’s application to expand use of Nucala for COPD
The British drugmaker’s application is supported by data from the Phase 3 MATINEE trial, in 804 patients with diverse COPD phenotypes, with elevated blood eosinophil counts
AstraZeneca invests $2.5bn to build new R&D centre in Beijing, China
The investment, part of a strategic partnership with the Beijing Municipal Government and the Beijing Economic-Technological Development Area Administrative Office, aims to advance life sciences in China